ZTS

Zoetis Inc. Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Zoetis Inc. is a global leader in the animal health industry, operating in two geographic segments: the United States and International. The company markets products for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). A significant accounting change occurred effective January 1, 2026, aligning the fiscal year-end of international subsidiaries to December 31, eliminating a previous one-month reporting lag. Prior period data has been recast to reflect this change.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 3% ($64 million) year-over-year. On an operational basis (excluding foreign exchange), revenue decreased 1%. The reported growth was driven by a 4% favorable foreign exchange impact.
• Segment Performance:
  • U.S. Segment: Revenue declined 8% ($93 million) due to softer demand in companion animal products (dermatology, Simparica Trio) and generic competition. Livestock revenue grew 7%.
  • International Segment: Revenue increased 17% ($164 million), driven by 9% operational growth and 8% favorable foreign exchange. Growth was broad-based across companion animal and livestock categories.
• Expenses:
  • R&D: Increased 11% ($18 million) due to higher project investments and compensation costs.
  • Restructuring: The company incurred $22 million in restructuring charges in Q1 2026, primarily for employee termination costs related to organizational refinements. There were no such charges in Q1 2025.
  • Interest Expense: Increased 15% ($8 million) due to a higher average debt balance.
• Cash Flow: Operating cash flow decreased $114 million to $401 million, attributed to timing of receipts/payments and higher inventory build-up. Financing activities used $840 million, primarily for share repurchases ($606 million) and dividends ($224 million).

Guidance, Outlook, and Risks

• Acquisitions: Zoetis entered a definitive agreement to acquire Neogen Corporation's animal genomics business, expected to close in the second half of 2026.
• Capital Allocation: The company continues an aggressive share repurchase program. As of March 31, 2026, $1.8 billion remained under the $6 billion authorization. In Q1, 4.8 million shares were repurchased for $606 million.
• Debt Structure: In late 2025, the company issued $2.0 billion in convertible senior notes and $1.85 billion in senior notes to refinance maturing debt. The company remains in compliance with all financial covenants.
• Risks and Contingencies:
  • Tax Audit: The company is under audit by the IRS for tax years 2017 and 2018. The IRS has proposed an additional tax liability of approximately $450 million. Zoetis disagrees with the position and believes its current accrual is appropriate.
  • Legal: Ongoing environmental litigation in Brazil (Ulianopolis) regarding waste disposal; the company is collaborating on a remediation plan.
  • Macro: Risks include tariffs, trade protection measures, foreign exchange volatility, and disease outbreaks affecting livestock demand.

Investor Verification Checklist

• Operational Revenue Decline: Verify the drivers behind the 1% operational revenue decline, specifically the impact of generic competition on key franchises like Convenia and Cerenia.
• Restructuring Impact: Assess the long-term cost savings expected from the $22 million in Q1 restructuring charges and organizational refinements.
• IRS Audit Exposure: Monitor the status of the IRS audit regarding the 2018 tax return and the potential $450 million proposed adjustment.
• Neogen Acquisition: Track the regulatory approval process and expected closing timeline for the Neogen animal genomics business acquisition.
• Share Repurchase Pace: Evaluate the sustainability of the current repurchase rate ($606 million in Q1) against the remaining $1.8 billion authorization and future cash flow needs.